Merck prevails in US safety litigation over Gardasil HPV vaccine
A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...
Merck opens $1 billion addition in north Durham to boost production of popular vaccine
The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a ...
NJBIZ2d
Merck opens $1B vaccine production facility (updated)
Merck says those efforts aim to expand domestic manufacturing as well as research and development capabilities. Additionally, the moves created new jobs. Merck also said it expects to invest ...
Fierce Pharma7d
In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ
A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, ...
Hosted on MSN1mon
Merck eyeing 2025 launch for easier-to-use Keytruda
Keytruda, also known as pembrolizumab, accounts for the bulk of the Rahway, New Jersey-based pharmaceutical giant's revenue. However, with its U.S. patent exclusivity ending in 2028, Merck (NYSE ...
Nasdaq1mon
What Are Wall Street Analysts’ Target Price for Merck Stock?
Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $252.4 billion by market cap, the company delivers health solutions through its prescription ...
Merck's Oncology Strength: Beating Wall Street Again
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.